thank stand welcome pharmaceutical third quarter earn conference call operator instruction would like hand conference speaker today vice president investor relation please ahead vice president thank good morning good afternoon good even everyone listen around globe thank interest pharmaceutical welcome third quarter conference call archive webcast available website join today call founder president chief executive officer founder president chief scientific officer executive vice president head commercial executive vice president chief financial officer prepare remark open call would also like remind remark make today call include forward look statement statement include limit relate product business financial forecast guidance development program relate anticipate milestone collaboration finance regulatory matter payer coverage reimbursement issue intellectual property pending litigation proceed competition forward look statement subject risk uncertainty could cause actual result event differ materially project statement complete description material risk find file unite state security exchange commission include form period file earlier today undertake obligation update forward look statement whether result information future event otherwise addition please note measure discuss today call information regard financial measure reconciliation measure available financial result press release access website call conclude available answer question turn call president chief executive officer founder president chief executive officer executive begin remark note last call least position make transition decide want make news report explain news move commercial organization excite replacement fully place hear role remarkable quick point join company stock around significantly higher thank great service turn business turn another strong performance third quarter mark significant double digit bottom line growth continue operate leverage possible result truly exceptional execution colleague across entire company production commercial support despite challenge face impose pandemic core business contribute solid underlie growth additionally secure third supply agreement unite state government investigational antibody cocktail treat prevent certain population initial delivery fuel additional growth momentum quarter broad grow pipeline include clinical stage candidate many expect enter clinic short order continue advance innovation secure long term growth potential importantly pipeline continue largely compose comprise internal innovation increasingly supplement external relationship bring novel modality include create unique treatment option combination approach outline momentarily third quarter begin global sale billion grow percent compare prior year sale grow percent reflect recovery anti category share gain lead anti treatment retinal disease strength opportunity steady growth continue despite potential upcoming competition currently disruptive game change engine anti space treat retinal disease continue remarkable deliver commercially clinically across wide spectrum type inflammatory disease third quarter global sale grow percent billion growth contribution inside outside unite state continue improve operate leverage alliance announce positive result four phase registrational study recent month young child atopic dermatitis three potential indication eosinophilic esophagitis prurigo nodularis chronic spontaneous urticaria expand asthma label include child testament efficacy also safety chronic treatment type inflammatory disease several disease opportunity clinical development expansion possibility significant remarkable medicine already change life hundred thousand patient oncology global sale million grow percent despite challenge impose oncology market work hard leader cutaneous squamous cell carcinoma progress basal cell carcinoma lung cancer launch also prepare potential launch much larger opportunity combine chemotherapy small cell lung cancer continue grow importance increase utilization treatment accept priority review biologic license application treatment prophylaxis certain patient also review expand emergency authorization certain patient exposure prophylaxis outside unite state antibody cocktail receive full approval conditionally approve emergency temporary pandemic authorization currently place country potential broad range prevention treatment application prophylaxis treatment patient give anticipation infection time increase utilization appropriate case need prophylaxis immunocompromised individual anticipate ongoing role global demand warrant capacity produce four million five million gram exclude supply contribution conclude close growth momentum strong outlook continue growth fuel breadth depth pipeline bright turn call scientific founder president chief scientific officer director thank pick leave story mention robust development program involve people date provide evidence potential various prevention treatment application exposure prophylaxis treat patient unite state currently authorize also review full approval treatment prevention certain patient action date appreciate widespread vaccination best broadly protect many people possible recent research also reveal important coverage provide vaccine leave individual uniquely vulnerable particularly several million immunocompromised people unite state alone remain pandemic first many immunocompromised population respond optimally vaccination even booster second breakthrough infection general population still occur vaccination mean immunocompromised people continue risk encounter individual even within highly vaccinate population therefore believe could particular importance immunocompromised individual remain unprotected also highest risk develop severe disease include people certain hematologic cancer example lymphoma leukemia myeloma people take certain immunosuppressive medicine disease multiple sclerosis rheumatoid arthritis organ transplant recipient primary unite state submit data request expand exist emergency authorization include chronic prevention back reflect commitment immunocompromised recently begin trial optimize prophylaxis population include evaluation extend dose current cocktail retain potent activity know variant interest include delta variant however virus continue mutate evolve thus previously discuss advance novel anti spike protein antibody cocktail clinical development proactively case novel innovative antibody cocktail retain potency potential variant require future move ophthalmology report encourage line data high dose aflibercept phase study small proof concept study meet primary efficacy endpoint higher proportion patient eight milligram aflibercept group retinal fluid compare patient treat currently approve milligram dose week safety signal observe comparison currently approve milligram dose large phase trial evaluate high dose aflibercept dose interval every week every week fully expect report result second half phase data crucial understand overall efficacy safety convenience high dose aflibercept move remarkable clinical success across many different allergic type inflammatory disease validate early long stand hypothesis condition drive fundamental pathway interleukin four interleukin pathway effectively block whether disease manifest asthma chronic nasal airway atopic dermatitis prurigo nodularis skin eosinophilic esophagitis clinical data demonstrate important impact many condition initially seem relate past month demonstrate positive result four separate pivotal study tremendous accomplishment stem vision dedication great news patient suffer type inflammatory disease recent phase trial atopic dermatitis infant child young month meet primary secondary endpoint lower observe rate skin infection group compare placebo detail result trial present future medical meet data submit year data reinforce establish efficacy safety profile million patient treat date also report recent phase data eosinophilic esophagitis progressive disease damage esophagus ability patient trial manifestation disease severe previously undergo endoscopic esophagus symptomatic relief study patient take weekly approximate point improvement symptom questionnaire represent percent improvement compare point improvement placebo update reinforce previously report phase result week follow result recently present unite week virtual congress completion regulatory file adolescent adult plan early also recently report positive result phase trial another inflammatory skin condition know prurigo nodularis underdiagnosed disease characterize extreme itch skin trial meet primary secondary endpoint comparison placebo include reduction itch baseline week achieve clear skin improvement quality life second trial prurigo nodularis fully expect read first half regulatory submission plan year excite phase data lead regulatory approval would approve different allergic type inflammatory disease indication include patient young month move oncology positive phase data combination chemotherapy first line advance small cell lung cancer present meet data mark inhibitor demonstrate positive phase result first line small cell lung cancer irrespective histology monotherapy combination chemotherapy study conduct patient population include difficult treat disease characteristic reflect everyday clinical practice rapidly progress toward regulatory submission chemotherapy combination across histology expression level could unlock opportunity help larger population lung cancer patient turn hematology upcoming society hematology annual meet provide update develop hematology portfolio presentation provide data update potentially registrational first human trial bispecific antibody test patient heavily pretreated multiple myeloma major advance treatment patient fail several prior line therapy potential utility target bispecific limit patient population data development plan virtual investor event schedule regard odronextamab bispecific please recruitment potentially pivotal trial since partial clinical hall lift earlier year exploration subcutaneous formulation odronextamab track start year plan initiate broader phase program bispecific development program solid tumor progress unique approach include bispecific monotherapy ovarian cancer combination costim addition expect initial data costim patient prostate cancer also excite costim clinical program across multiple high cancer include lung cancer clinical stage bispecific antibody drug conjugate present indecipherable realm drug conjugate link potentially best class bispecific antibody conclusion oncology approach important phase several novel phase program clinical development expect come month also large phase study plan three first line advance melanoma pembrolizumab monotherapy comparator large registrational program hematology oncology bispecifics excite potential important investment portfolio bring patient would like conclude genetics medicine collaboration update uniquely position combine product establish biologics portfolio emerge find genetics medicine effort part collaboration look forward multiple update program already mention meet show first human data antibody combination inhibit present initial result healthy volunteer support development first kind combination antibody therapeutic early data monotherapy indecipherable achieve complete terminal complement blockade necessary adequate disease control paroxysmal antibody specific target protein could provide patient lower dose therapy convenient extend dose regimen provide complete inhibition result better efficacy breakthrough also recently initiate phase study test antibody combination start next year plan test combo naive switch patient test standard care therapy include eculizumab study potential show true benefit combination approach treatment disease also collaboration initial genetic target discovery reach stage clinical readout nonalcoholic disease find treatment option difficult approach silence gene identify potential target recall discover people protective gene variant percent percent lower odds chronic liver disease collaborator show initial healthy volunteer safety data target upcoming later month finally genetics center publish manuscript nature highlight achievement milestone sequence almost million exomes biobank database nature paper first time describe rare variant gene could potential drug target disease hypertension diabetes asthma others turn call executive vice third quarter business performance demonstrate strength commercial portfolio execute line brand maximize opportunity diversify sustainable growth ongoing launch first highlight recent achievement antibody cocktail available emergency authorization third quarter sale million primarily base initial delivery third government agreement announce demand accelerate sharply third quarter promise treatment option continue help fight surge case increasingly standard care outpatient treatment post exposure prophylaxis appropriate patient field educator continue support stakeholder healthcare system administration site case thankfully decrease last several week demand remain high many patient receive treatment broad therapeutic application current potential future integration across spectrum disease exposure prevention hospitalization look forward decision application full approval expect beyond deliver strong growth core business third quarter start third quarter global sale grow percent year year billion sale grow percent year year nearly billion base category recovery competitor share gain secure nearly percent overall category percent brand category base overall platform efficacy safety convenience positive early indicator unbranded direct consumer campaign educate patient diabetic disease importance vision care retina specialist applaud effort encourage diabetic patient seek treatment prevent irreversible vision loss competitive profile couple favorable underlie demographic trend give confidence ongoing leadership position retinal disease turn global sale million sale reach million despite continue impact patient start indication launch early stage vast majority sale come advance cutaneous squamous cell carcinoma systemic treatment build success quickly establish standard care advance basal cell carcinoma patient second line inhibitor appropriate lung cancer work secure physician experience competitive monotherapy treatment option look forward potential chemotherapy combination approval would unlock much larger group first line patient eligible anti briefly turn treat patient prior standard care continue initiation switch category patient illustrate innovative patient identification effort support future rare disease finally third quarter global sale grow percent year year billion sale grow percent billion growth drive across approve indication patient start level atopic dermatitis prescribe trend strong across spectrum moderate severe disease include adolescent pediatric patient continue capture market growth base establish efficacy safety breadth current indication unmatched physician patient experience continue substantial potential growth atopic dermatitis include child young month broadly dermatology potential indication chronic spontaneous urticaria prurigo nodularis respiratory disease continue surpass recent competitive biologic launch asthma ongoing potential differentiate competitive profile label expansion market recover asthma relate emergency room visit nearly percent launch pediatric asthma underway extend treatment option child suffer often disease label also recently update include additional marker type inflammation call extend eligible population beyond high eosinophilic level addition prescribe steroid dependent asthma regardless eosinophilic level nasal continue growth lead market despite competition continue prefer choice regardless prior surgery summary commercial continue deliver strong growth across portfolio differentiate brand ongoing potential future launch remain track long term growth turn call executive vice president finance chief financial officer conference call comment today financial result outlook basis applicable third quarter deliver strong bottom line growth increasingly diversify revenue stream contribution robust core business third quarter total revenue grow percent year year billion total dilute income share grow percent year year income billion exclude revenue relate antibody cocktail total revenue grow percent versus prior year start third quarter recognize million sale consist largely initial delivery approximately government million dose contract announce collaborator record sale antibody cocktail know outside accordance agreement true payment global profit record additional million collaboration revenue fourth quarter expect deliver approximately supply approximately half record product sale give manufacture product supply market true payment global profit expect result collaboration revenue fourth quarter remain government contract expect deliver first quarter move collaboration product sale report worth million third quarter represent growth percent report basis percent constant currency basis total collaboration revenue million record million share profit sale outside total collaboration revenue million third quarter share profit commercialization million compare favorably share profit million prior year also recognize million sale milestone payment relate achievement billion sale collaboration roll month basis move operate expense decrease slightly million primarily lower spend development compare third quarter next expense increase percent year year million primarily relate growth initiative higher headcount good sell increase versus prior year million million primarily manufacture collaboration manufacture increase percent year year million drive higher production support grow sale finally effective rate percent third quarter shift cash flow balance sheet year date generate billion free cash flow quarter cash marketable security debt billion continue utilize strong balance sheet accordance capital allocation priority invest internal fund strategic external partnership return cash shareholder accordingly third quarter repurchase approximately million share conclude like provide select update guidance complete summary latest full year guidance available press release publish earlier morning update gross margin guidance approximately percent estimate inclusive expect payment true global profit antibody cocktail report good sell result expect gross margin percentage fourth quarter lowest year also update guidance range billion billion change guidance range relate update phase expense lower spend look ahead continue make investment commercial business broad pipeline long term growth particular expect advance critically important development program include late stage study three combo along brand comparators mention earlier advance program collaborator conclusion please third quarter invest robust pipeline drive sustain long term growth turn call back vice president conclude prepare remark like open call please ahead